- Issuer ticker
-
TRAW
- Reported as of
-
12 Jun 2023
- Net transaction value
-
-$1,791
Source evidence
Original filing metadata and source links for verification.
5 source fields
- SEC form
-
4
- Accepted by SEC
-
13 Jun 2023, 16:54:25 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Mark Guerin
Key filing fact
Mark Patrick Guerin filed Form 4 for Onconova Therapeutics, Inc. (TRAW) on 13 Jun 2023.
Key facts
- This page summarizes Mark Patrick Guerin's Form 4 filing for Onconova Therapeutics, Inc. (TRAW).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Jun 2023, 16:54.
Change
- Previous filing in this sequence was filed on 14 Mar 2023.
- Current net transaction value: -$1,791.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ONTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,500
- Change %
- +30%
- Price
-
- Shares after
- 23,691
- Date
- 12 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
ONTX
transaction
Common Stock
Tax liability
- Transaction value
- $1,791
- Shares
- -1,575
- Change %
- -6.6%
- Price
-
$1.14
- Shares after
- 22,116
- Date
- 12 Jun 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ONTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,500
- Change %
- -33%
- Price
-
$0.000000
- Shares after
- 11,000
- Date
- 12 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,500
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Explanation of responses
2 footnotes